Nuvation Bio Inc.

NYSE:NUVB

Biotechnology

Healthcare
$3.78 +1.03%

+$0.06 today

Market cap
$1.33B
Beta
1.56
P/E (TTM)
-12.8
EPS (TTM)
-$0.42
52W Low $1.81High $9.75

Volume 5.96M

Average 4.07M

NUVB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Nuvation Bio Inc.NYSE: NUVB

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 97.1%

Gross margin was 97.1% in Q2 FY2026, up 50.4 pp from a year earlier. On a trailing-twelve-month basis it was 93.9%, up 66.4 pp year over year.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
97.1%+3.9 pp QoQ
Last fiscal yearDec 2025
86.6%+76.5 pp YoY
LTMJun 2026
93.9%+66.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+50.4 pp——
1 year+76.5 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
86.6%
Year-over-year change
+76.5pp

Gross Margin vs competitors

How NUVB compares with its peers on the latest reported figures

  • NUVB's LTM Jun 2026 gross margin of 93.9% is the 2nd highest of the 8 companies compared; the peer median is 74.1%.
  • Its year-over-year change of +66.4 pp is the 3rd highest of 8, against a peer median of +0.8 pp.
NUVB Competitors Peer median
Gross Margin for NUVB and competitors
Company Period LTM level YoY 3-year change
VRDNViridian Therapeutics, Inc.LTM Jun 202699.6% -0.4 pp+0.0 pp
NUVBNuvation Bio Inc.LTM Jun 202693.9% +66.4 pp—
AUPHAurinia Pharmaceuticals Inc.LTM Jun 202690.4% +0.8 pp-7.3 pp
OCULOcular Therapeutix, Inc.LTM Mar 202687.2% -3.4 pp-3.9 pp
QUREuniQure N.V.LTM Mar 202674.1% +20.2 pp-7.3 pp
JANXJanux Therapeutics, Inc.LTM Mar 202654.1% +476.2 pp-10.5 pp
ABCLAbCellera Biologics Inc.LTM Sep 2026-18.7% -118.7 pp-24.7 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
EWTXEdgewise Therapeutics, Inc.FY2025— ——
VERAVera Therapeutics, Inc.FY2025— ——
GPCRStructure Therapeutics Inc.FY2025— ——
Peer median (excluding NUVB) 74.1%+0.8 pp-7.3 pp

Competitors are the stored peer set for NUVB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0007.87M62.9M
Cost of Revenue0007.08M8.44M
Gross Profit000795K54.46M
Gross Margin———10.1%86.6%
Research & Development69.04M87.82M71.29M524.19M115.11M
Selling, General & Admin24.28M31.92M28.53M69.23M151.56M
Operating Expenses93.32M119.73M99.82M593.42M267.52M
Depreciation & Amortization184K199K222K683K1.74M
EBITDA(86.66M)(104M)(75.58M)(566.92M)(189.21M)
EBITDA Margin———-7200.7%-300.8%
Operating Income(93.32M)(119.73M)(99.82M)(592.63M)(213.06M)
Operating Margin———-7527.3%-338.7%
Interest Income2.96M7.45M24.61M27.06M21.43M
Interest Expense000341K13.68M
Other Income / Expenses6.47M15.54M24.02M24.69M8.44M
Income Before Tax(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Pre-Tax Margin———-7213.8%-325.3%
Income Tax Expense00000
Net Income(86.85M)(104.2M)(75.8M)(567.94M)(204.63M)
Net Margin———-7213.8%-325.3%
EPS (Basic)(0.44)(0.48)(0.35)(2.11)(0.60)
EPS (Diluted)(0.44)(0.48)(0.35)(2.11)(0.60)
Weighted Avg Shares197.89M216.72M218.88M268.77M341.54M
Weighted Avg Shares (Diluted)197.89M216.72M218.88M268.77M341.54M

Nuvation Bio Inc.

NYSE:NUVB

Intrinsic Alpha fair value

Locked

Current Price

$3.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.